Gain Therapeutics stockholders approve doubling authorized common stock to 100M shares

Gain Therapeutics, Inc.

Stockholders approved amendment to increase authorized common shares from 50M to 100M.
All eight director nominees elected; Ernst & Young AG ratified as auditor for FY2025.
Vote results: 16.3M for share increase, 2.2M against, 12k abstain; 18.0M ratified auditor.
Adjournment proposal also approved to allow further proxy solicitation if needed.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Gain Therapeutics, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2025-06-24).

Change: charter amendment
Effective: 2025-06-24

Exact text from the filing

On June 24, 2025, Gain Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock from 50,000,000 shares to 100,000,000 shares.

View on SEC.gov

Browse all governance changes →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-062162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.